Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or New Jersey for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to New Jersey only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. New Jersey (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Naim Nazha (NPI 1730136854)

Field	Value
Entity Type	Individual
Organization	Naim Nazha
Address	411 New Rd
City	Northfield
State	NJ
ZIP	08225
Taxonomy	Medical Oncology Physician
NPI Enumerated	May 27, 2006

Payer Source	Total Paid
Medicare	$2.8M
Medicaid	$0

Key Findings

This provider is effectively a single-payer Medicare practice: total Medicare revenue is $2.8M while there is no Medicaid billing on file, so Medicaid does not contribute to this provider's revenue mix. The absence of Medicaid claims indicates limited state-level exposure and that commercial or Medicare lines likely underwrite the provider's full operations.

Revenue is highly concentrated in a few oncology injectables: the precomputed top 3 Medicare codes account for 73.2% of this provider's total Medicare revenue, and a single code, J9271, represents $1.5M (53.4% of Medicare revenue). That degree of concentration around high-cost biologic therapy implies most payer spend on this provider is driven by a small set of drugs rather than broad E/M services.

The code mix and volumes indicate a medical oncology infusion operation: high-volume biologic injections such as J9271 (pembrolizumab), J0897 (denosumab), and Q5119 (rituximab biosimilar) dominate revenue, alongside chemotherapy administration codes like 96413 and frequent infusion administration codes such as 96367 and 96365. Supportive therapy billing (Q5106 epoetin, Q5111 pegfilgrastim biosimilar) further signals routine management of chemotherapy-related toxicities and infusion-based supportive care.

This provider ranks as a high-volume national player on several specific oncology drugs: J9271 ranks #68 of 1841 providers nationally (96th percentile; notably above typical national volume for this code), J0897 ranks #294 of 10057 providers nationally (97th percentile; notably above typical national volume for this code), and Q5119 ranks #3 of 335 providers nationally (99th percentile; extreme outlier, far above typical national volume for this code). Those rankings position the provider well above peer norms for use of these agents and identify it as a concentrated national outlier for certain biosimilars.

Infusion and related E/M activity is also unusually high relative to peers: 99213 ranks #485 of 457151 providers nationally (100th percentile; extreme outlier, far above typical national volume for this code), 96367 ranks #12 of 4032 providers nationally (100th percentile; extreme outlier, far above typical national volume for this code), and 96372 ranks #73 of 58224 providers nationally (100th percentile; extreme outlier, far above typical national volume for this code). These patterns indicate very high patient throughput for infusion encounters and repeated administration services compared with national peers.

The provider shows substantial uptake of biosimilars and supportive injectable agents: Q5111 (pegfilgrastim biosimilar) produced $64.9K in revenue and ranks #44 of 123 providers nationally (65th percentile; typical, unremarkable volume for this code), while Q5106 (epoetin biosimilar) totaled $94.1K and ranks #8 of 695 providers nationally (99th percentile; extreme outlier, far above typical national volume for this code). High-listed ranks for biosimilars suggest operational emphasis on parenteral supportive therapies alongside primary oncology biologics.

Given the $2.8M Medicare revenue base and the concentration of spend in a few high-cost injectables (top 3 = 73.2%), payers reviewing this provider should anticipate concentrated drug spend risk and prioritize drug reimbursement terms and utilization management for J9271, J0897, and Q5119. The provider's zero Medicaid billing further simplifies state-level exposure but means Medicare price and utilization trends will largely define payer cost impact.

This provider is an established practice with longevity in the Medicare program: NPI enumeration date is 2006-05-27 (~20 years ago), which supports the view that the high-volume infusion and biologic prescribing patterns reflect sustained operational focus rather than a short-term fluctuation. Combined tenure and the repeated extreme-percentile rankings indicate stable, long-running high-volume oncology infusion activity rather than a transient billing anomaly.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

38 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	34,600	$40	$1.5M
J0897	Injection, denosumab, 1 mg	19,860	$20	$357.5K
Q5119	Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg	8,380	$20	$192.7K
99213	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the…	2,350	$70	$167.1K
Q5106	Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units	15,680	$10	$94.1K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	740	$120	$86.8K
Q5111	Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg	620	$100	$64.9K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	610	$100	$61.7K
96367	The provider administers an additional intravenous infusion or infusions, after an initial infusion, of a different medication or substance for a period up to one hour to prevent, treat, or diagnose…	2,300	$30	$57.4K
96365	The provider administers the initial intravenous infusion of a medication or other substance for a period up to one hour to prevent, treat, or diagnose a condition or disease.	940	$50	$50.7K

Showing 1–10 of 38

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 38 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. New Jersey Distribution

Naim Nazha — 15 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — New Jersey

Full comparison — all codes billed, vs. state median

38 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	1	50	10,650	$40	$580.7K
Q5119	1	10	3,620	$20	$98.7K
J0897	9	380	3,060	$20	$87.8K
Q5111	20	50	580	$110	$76.6K
J3490	2	120	70	$230	$30.2K
Q5106	3	50	3,820	$10	$30K
96413	12	230	190	$110	$26.6K
85025	21	750	120	$10	$24.2K
99214	1,459	13,640	130	$90	$23.6K
99213	10	14,090	100	$70	$13.1K

Showing 1–10 of 38

Related Providers

Other providers that share a Tax Identification Number (TIN) with Naim Nazha, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
James Dalzell	NJ	Radiation Oncology Physician	$1.1M	$0
Le Wang	PA	Hematology (Internal Medicine) Physician	$270.4K	$0
Zoryana Stoyko	NJ	Hematology & Oncology Physician	$189.3K	$0

Nearby Providers

Other providers in the same ZIP code as Naim Nazha, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Reliance Medical Group LLC	NJ	Specialist	$0	$9.4M
Thomas Margolis	NJ	Ophthalmology Physician	$2.5M	$0
Scott Foxman	NJ	Ophthalmology Physician	$2M	$0
Brett Foxman	NJ	Ophthalmology Physician	$1.6M	$0
Jaime Epstein	NJ	Mental Health Counselor	$140.9K	$1.4M
Daniel Connors	NJ	Ophthalmology Physician	$1.5M	$0
David Feng	NJ	Specialist	$798.8K	$0
Francis Previti	NJ	Surgery Physician	$434.6K	$0
M Seplow	NJ	Psychiatry Physician	$383.5K	$0
Pryiesh Thakkar	NJ	Nephrology Physician	$349.1K	$0

Naim Nazha — Billing Profile & Reimbursement Data

Sign up for Naim Nazha — Billing Profile & Reimbursement Data policy alerts

Naim Nazha — Billing Profile & Reimbursement Data

Sign up for Naim Nazha — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References